Abstract
Chronic hepatitis C (CHC) is associated with increased presenteeism and absenteeism rates of patients. This creates a large economic burden for both employers and society. Ledipasvir/Sofosbuvir (LDV/SOF) is indicated for the treatment of CHC providing high efficacy, excellent tolerability and substantial quality of life improvement in clinical trials. An economic model was developed to assess the impact of LDV/SOF treatment vs. no treatment on work productivity for German CHC genotype 1 (GT1) patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
